CBU
TGTX icon

CIBC Bancorp USA’s TG Therapeutics TGTX Stock Holding History

CIBC Bancorp USA’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Buy
8,326
+749
+10% +$30.7K ﹤0.01% 1347
2026
Q1 		$252K Buy
+7,577
New +$226K ﹤0.01% 1499
2025
Q3 		$559K Buy
+15,483
New +$510K ﹤0.01% 821

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

CIBC Bancorp USA's TGTX Position: Q2 2026 in Review

CIBC Bancorp USA increased its TG Therapeutics (TGTX) stake by 9.9% in Q2 2026, buying an estimated $30.7K and bringing the position to 8,326 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #1347.

CIBC Bancorp USA first reported a position in TGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $559K in Q3 2025. 405 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • CIBC Bancorp USA held 8,326 shares of TG Therapeutics worth $457K as of Q2 2026.
  • CIBC Bancorp USA bought 749 TG Therapeutics shares in Q2 2026, an estimated $30.7K.
  • TG Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1347 holding.
  • CIBC Bancorp USA first reported a position in TG Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's TG Therapeutics position peaked at $559K in Q3 2025.
  • 405 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.